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Background: Activating mutations of K-Ras gene have a well-established role as
predictors of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal
cancer (mCRC) patients. Their prognostic value is controversial, and no data regarding
the prognostic value of mutation rate, defined as the percentage of mutated alleles/
tumor sample, are available. We aimed to evaluate the prognostic value of K-Ras
mutation rate in a homogenous cohort of mCRC patients receiving first-line doublet
plus bevacizumab.
Patients and methods: This retrospective study enrolled 397 K-Ras mutant mCRC
patients from 6 Italian centers, and 263 patients were fully evaluable for our analysis.
K-Ras mutation rate was assessed by means of pyrosequencing analysis. Patients with
less than 60% of cancer cells in tumor tissue were excluded. No patients received
anti-EGFR containing anticancer therapy, at any time. Median mutation rate was 40%
and was adopted as cut-off value. The primary endpoint was PFS, OS was a secondary
endpoint.
Results: At univariate analysis, a K-Ras mutation rate higher than 40% was
significantly associated with lower PFS (7.3 vs 9.1 months; P < 0.0001) and OS (21 vs
31 months; P = 0.004). A multivariate model adjusted for age at diagnosis, site of origin
of tumor tissue (primary cancer vs metastases), referral center, number of metastatic
sites, and first-line chemotherapy backbone, showed that K-Ras mutation rate
remained a significant predictor of PFS and OS in the whole population.
Conclusions: Our data demonstrate an association between K-Ras mutation rate and
prognosis in patients treated with bevacizumab-containing first-line therapy for
mCRC. These data deserve to be verified in an independent validation set.
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